Condition category
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status

Plain English Summary

Background and study aims
End-stage liver disease is where the liver cannot function properly because of long-term damage, for example from heavy alcohol use or hepatitis virus infection. Liver transplantation is the current most effective treatment for end-stage liver disease. The donor liver is usually stored on ice during transportation to the recipient patient. This is to reduce damage to the organ while it is out of the body and has no oxygen supply. However, when the liver is connected to the recipient's blood supply, there can be damage to the liver cells (reperfusion injury) caused by the sudden restarting of normal processes, including the sudden change from no oxygen to normal oxygen levels. This study aims to investigate whether the reperfusion injury can be reduced by gently warming the liver and flushing it through with liquid containing oxygen in a machine perfusion apparatus before transplantation.

Who can participate?
Adults on the list for liver transplantation at the University Hospital Essen who consent to participating in the study.

What does the study involve?
Participants will be randomly allocated to one of two groups. In both groups the recipient preparation and transplant surgery will be carried out as usual. In the control group, the donor liver will be prepared as usual. In the study group, the donor liver will be attached to a machine that pumps liquid containing oxygen through it via the artery and vein that circulate blood through it normally. The liquid will be gradually warmed up so that by the time the liver has been receiving the liquid for 60 minutes, the temperature will be 20°C. The total time that the liver is receiving the liquid before it is transplanted into the recipient will be at least 90 minutes.

What are the possible benefits and risks of participating?
This procedure has been tested in animals and in an initial study in humans and is thought to be safe. The study group might benefit from reduced reperfusion injury to the transplanted liver, which might mean that it regains full function more quickly.

Where is the study run from?
University Hospital Essen

When is the study starting and how long is it expected to run for?
August 2016 to February 2021

Who is funding the study?
The Else Kröner Fresenius Foundation

Who is the main contact?
Professor Thomas Minor,

Trial website

Contact information



Primary contact

Prof Thomas Minor


Contact details

Hufelandstr. 55

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

Controlled Oxygenated Rewarming as Novel Endischemic Therapy for cold stored liver grafts (CORNET): a prospective randomized controlled trial



Study hypothesis

1. Controlled oxygenated rewarming of the cold preserved liver graft prior to warm reperfusion will mitigate rewarming/reperfusion injury upon liver transplantation.
2. Functional data obtained during ex-situ machine perfusion will help to evaluate graft integrity prior to transplantation

Ethics approval

Ethics Committee, Medical Faculty, University of Duisburg-Essen [Ethik Kommission der Medizinischen Fakultät der Universität Duisburg-Essen], 29/11/2016 (amended 27/09/2018), 16-7110 BO

Study design

Single-center randomized controlled parallel-arm pilot study

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details to request a patient information sheet


Preservation and transplantation of liver grafts


Randomisation: 1:1 block randomisation. The donor liver is randomised by our study design. Only patients who had given informed consent to participate in the study will be included in the randomisation and the study.
Control study arm: Procedure according to usual clinical standards without any experimental treatment.
Experimental study arm: Livers will be put on a CE-certified organ perfusion machine (Liver Assist®, Fa. Organ Assist, The Netherlands) and machine perfusion started via the hepatic artery and hepatic portal vein in a closed circuit with Belzer machine perfusion solution. Perfusate will be oxygenated to a pO2 >500mmHg via two oxygenators included in the arterial and portal circuits. The temperature of the perfusate will be increased slowly over time to reach a steady state of 20°C after 60 min. Total perfusion time will be 90 min or slightly longer, if the recipient preparation time exceeds the minimum perfusion time of 90 min (for further details see: Hoyer DP et al. Controlled Oxygenated Rewarming of Cold Stored Livers Prior to Transplantation: First Clinical Application of a New Concept. Transplantation. 2016;100:147-52).

Intervention type



Drug names

Primary outcome measure

Serum peak value of aspartate aminotransferase (AST) during the first 3 days after transplantation

Secondary outcome measures

1. Death assessed using patient medical records from admission until 3 months after transplantation
2. Early Allograft Dysfunction (EAD) according to Olthoff (bilirubin >10 mg/dl or INR >1.6 at POD 7, or peak-AST >2000 U/l during first week after transplantation, based on patient medical records from admission until 1 week after transplantation
3. Re-transplantation assessed using patient medical records from admission until 3 months after transplantation
4. Duration of stay in intensive care unit assessed using patient medical records
5. Ischemia reperfusion injury based on laboratory tests assessed using patient medical records from admission until 1 week after transplantation
6. Liver maximum function capacity assessed using LiMAx® test 1 day after transplantation
7. Evaluation of correlation of machine perfusion parameters (obtained during ex vivo machine perfusion) with ulterior graft function after transplantation as assessed using patient medical records from admission until 3 month after transplantation
All patients are observed for 7 days following transplantation on a daily basis. Follow up includes additional observations on the day of discharge and 3 months after transplantation. Patients are followed until 3 months after the last patient is randomised for this trial and are asked to attend clinical routine follow up subsequent to termination of the study.

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

Inclusion criteria for the recipient:
1. Aged ≥18 years
2. Indication for liver transplantation
3. Listed as 'transplantable' at Eurotransplant
4. Resident in Germany
5. Provided informed consent

Inclusion criteria for donor liver:
1. Expanded criteria donor
2. Donor liver offered to the Transplantation Clinic Essen
3. Requiring one of the following criteria:
3.1. Age of donor >65 years
3.2. Intensive care including ventilation of the donor for >7 days
3.3. Obesity in the donor, i.e. BMI >30 kg/m2
3.4. Serum sodium >165 Mol/l,
3.5. Aspartate aminotransferase (AST/GOT) or alanine aminotransferase (ALT/GPT) >3 x normal
3.6. Serum bilirubin >3 mg/dl (last value prior to donor listing)
3.7. Liver steatosis (histologically confirmed) >40%

Participant type


Age group




Target number of participants


Participant exclusion criteria

1. High Urgency (HU) listing
2. Re-transplantation
3. Simultaneous participation in another preservation trial
4. Severe allergic diathesis
5. HIV-positive

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

University Hospital Essen
Hufelandstr. 55 45147 Essen Germany

Sponsor information


University Hospital Duisberg-Essen

Sponsor details

Hufelandstr. 55

Sponsor type

Hospital/treatment centre



Funder type


Funder name

Else Kröner-Fresenius-Stiftung

Alternative name(s)

Else Kroner-Fresenius Foundation, EKFS

Funding Body Type

private sector organisation

Funding Body Subtype




Results and Publications

Publication and dissemination plan

Dissemination of the results is planned by publication in a high-impact peer reviewed journal.

IPD sharing statement:
The data sharing plans for the current study are unknown and will be made available at a later date

Intention to publish date


Participant level data


Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes